UBS Maintains Neutral on AbbVie, Raises Price Target to $260

Benzinga Newsdesk www.benzinga.com Positive 74.8%

Neg 0% Neu 0% Pos 74.8%

UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $230 to $260.

Comments

No comments yet. Be the first!